| |
Overall population*
|
All 90-day survivors
|
90-day in-hospital
|
|---|
|
Parameter
|
Placebo (n = 1157)
|
AT III (n = 1157)
|
Placebo (n = 437)
|
AT III (n = 460)
|
Placebo (n = 55)
|
AT III (n = 63)
|
|---|
|
Age (years; mean ± SD [range])
|
58 ± 17 (18–96)
|
57 ± 17 (18–93)
|
53 ± 17 (18–96)
|
53 ± 17 (18–88)
|
57 ± 15 (22–81)
|
56 ± 14 (21–79)
|
|
Sex (%)
| | | | | | |
|
Male
|
61
|
62
|
62
|
64
|
67
|
65
|
|
Female
|
39
|
38
|
38
|
36
|
33
|
35
|
|
Country (%)
| | | | | | |
|
USA
|
15
|
15
|
14
|
15
|
6
|
6
|
|
Czech Republic
|
11
|
11
|
12
|
11
|
18
|
10
|
|
South Africa
|
11
|
11
|
9
|
8
|
2
|
5
|
|
UK
|
8
|
8
|
9
|
9
|
13
|
13
|
|
Denmark
|
7
|
7
|
6
|
7
|
6
|
11
|
|
Germany
|
6
|
6
|
6
|
5
|
4
|
8
|
|
Other (13 countries)
|
40
|
40
|
43
|
46
|
53
|
48
|
|
SAPS II risk group (%)
| | | | | | |
|
Moderate risk (<30%)
|
27
|
29
|
43
|
40
|
24
|
24
|
|
High risk (30–60%)
|
45
|
42
|
40
|
43
|
36
|
41
|
|
Very high risk (>60%)
|
28
|
29
|
17
|
18
|
40
|
35
|
|
Admitting diagnosis (%)†
| | | | | | |
|
Respiratory system
|
34
|
35
|
33
|
34
|
33
|
24
|
|
Digestive system
|
28
|
27
|
29
|
27
|
38
|
40
|
|
Genitourinary system
|
8
|
6
|
11
|
8
|
4
|
2
|
|
Injury
|
6
|
7
|
5
|
7
|
0
|
10
|
|
Other
|
24
|
24
|
22
|
25
|
26
|
25
|
|
Concomitant heparin (%)
| | | | | | |
|
No
|
30
|
30
|
29
|
32
|
13
|
30
|
|
Yes
|
70
|
70
|
71
|
68
|
87
|
70
|
- *All 2314 patients evaluable for efficacy in KyberSept study. †According to the International Classification of Diseases (9th edition). Percentages may not add to 100 because of rounding. AT, antithrombin; SAPS, Simplified Acute Physiology Score.
